« Back

Management team

DAVID PROIA, Ph.D. DAVID PROIA, Ph.D.
David enjoys long distance running and has completed three marathons, including the 2014 Boston Marathon.
DAVID PROIA, Ph.D.
Vice President, Oncology

A veteran biologist and pharmacologist with a successful track record of discovering and developing new oncology therapeutics from concept through IND and late-stage clinical studies.

David comes to ROME after serving as the Senior Director of In Vivo Pharmacology at C4 Therapeutics and project leader on multiple programs, including CFT7455 (IKZF1/3 degrader), which recently entered Phase 1 studies in patients with relapsed or refractory multiple myeloma and non-Hodgkin’s lymphoma. David has significant experience in all aspects of drug discovery, from target selection and validation to drug candidate selection, with broad knowledge across multiple disciplines, including chemistry, cell pharmacology, target biology, in vivo pharmacology, translational medicine, DMPK, CMC and toxicology. Prior to C4, David was the Director of Cancer Biology and In Vivo Pharmacology at Synta Pharmaceuticals and a Scientist at AstraZeneca. David earned his B.S. in biochemistry from Worcester Polytechnic Institute and his Ph.D. in molecular and cellular biology from Baylor College of Medicine.